210 filings
Page 7 of 11
8-K
6t2e4iyr4canlgyq
9 Sep 19
Other Events
12:00am
S-8
sx52c
7 Aug 19
Registration of securities for employees
5:31pm
8-K
vfq4u3byh heykrzos
7 Aug 19
Ovid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress
4:39pm
8-K
00n2weh
2 Jul 19
Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome
8:05am
8-K
wwy53kgvf9zp414o 7d
27 Jun 19
Regulation FD Disclosure
12:04pm
8-K
7bq1lwkds2payhx
27 Jun 19
Other Events
8:05am
8-K
wjvmlnr
18 Jun 19
Other Events
8:10am
8-K/A
i8twujq
17 Jun 19
Entry into a Material Definitive Agreement
4:30pm
8-K
1iq68497d xvqq
10 Jun 19
Submission of Matters to a Vote of Security Holders
5:26pm
8-K
4bti6g vttt
15 May 19
Entry into a Material Definitive Agreement
5:29pm
8-K
k10gh9b0zi k7el
7 May 19
Ovid Therapeutics Reports First Quarter 2019 Financial Results
8:05am
DEFA14A
uvf8t7zc
24 Apr 19
Additional proxy soliciting materials
5:30pm
8-K/A
2d2miioyl1eux0dl
28 Mar 19
Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline
12:27pm
8-K
sw1 qmx6gm
28 Mar 19
Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline
8:02am
8-K
g14ebm1tkomt25n
21 Mar 19
Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary
8:02am
8-K
xi29k0sijypaj1bau
11 Mar 19
Regulation FD Disclosure
2:51pm